Ann: Webcast Available of KOL Meeting, page-4

This is a really helpful presentation. It is impressive but it also contains some useful information for all shareholders (if you have the time to go through it - I'd recommend spending some time one evening or on the weekend going through it). The development of 210 is nicely told and the market potential is undoubtedly very attractive. It also gives the audience a very good understanding of the diligent approach the company has taken to drug development and that is why I remain confident that there will be partnering discussions of substance in the near term (likely to be for the more developed therapeutics) and in the long run too (for the earlier stage products). GLTA